San Francisco, California. – October 19, 2019 – OKAVA Pharmaceuticals, Inc., a clinical stage research and development company focused on diseases of aging in dogs and cats, announced today entering into a strategic partnership with Nano Prescison Medical, Inc. (NPM). This collaboration if focused on the development of miniaturized, long-term biopharmaceutical implants for feline obesity and diabetes with the goal of guaranteeing adherence, and potentially to improve tolerance to this medication. The proprietary, novel drug-device combination product (OKV-119) utilizes industry-leading drug delivery technology, NanoPortal™, to develop months long drug release of the GLP-1 exenatide for veterinary use.

“An alarming percentage of pet owners are unable to medicate their dogs and cats because of the challenges associated with drug administration. By leveraging NPM’s NanoPortal technology, we can overcome the challenges of medication non-adherence,” said Michael Klotsman, PhD, chief executive of OKAVA. “By adopting state-of-the-art human technologies, our goal is to bring next generation veterinary therapeutics, with superior product profiles at affordable prices, to the market in order to address unmet medical needs of household pets.”